PANEL 06 // THE QUESTION INDEX
BPC-157 TB-500 FAQ, answered from the record
Direct answers on the Wolverine blend — definition, mechanism, dose context, safety, and the regulatory record — each scanned to its source where it makes a quantitative claim.
Definition and difference
These answers cover what the BPC-157 TB-500 blend is, what its constituents are, and how they differ. Each is a direct answer first, context second.
What is BPC-157 and TB-500?
Two distinct synthetic peptides combined in the "Wolverine" research blend: BPC-157, a 15-amino-acid pentadecapeptide derived from a human gastric-juice protein (the cytoprotective, angiogenic channel) [1], and TB-500, an N-acetylated heptapeptide (Ac-LKKTETQ) from the actin-binding region of Thymosin Beta-4 (the cell-migration channel) [3][5].
What is the Wolverine peptide blend?
A research-community name for a two-peptide pairing of BPC-157 and TB-500, marketed and discussed as a tissue-repair "stack" [1]. It is not a single chemical entity, has no CAS number or molecular weight of its own, and is not an approved product anywhere.
What is the BPC-157 and TB-500 blend used for in research?
Its constituents are studied separately in tissue-repair models: BPC-157 in tendon, ligament, and muscle healing and angiogenesis in rodents [1][2], and TB-500 / Thymosin Beta-4 in actin-driven cell migration, re-epithelialization, and ligament healing [3][4]. The blend itself has no validated indication.
What is the difference between BPC-157 and TB-500?
BPC-157 is a 15-mer gastric-derived peptide acting through VEGFR2-Akt-eNOS angiogenesis and growth-hormone-receptor sensitization [1][2]; TB-500 is a 7-mer fragment of Thymosin Beta-4 acting through G-actin sequestration and cell migration [3][5]. Different structures, different mechanisms, paired for their complementary repair signals.
Mechanism and combination
These answers cover how each peptide works and what the "synergy" of the combination does — and does not — rest on.
Why are BPC-157 and TB-500 combined (the Wolverine stack)?
The rationale is a two-mechanism pairing: BPC-157 supplies a local cytoprotective and pro-angiogenic signal (VEGFR2-Akt-eNOS) while TB-500 / Thymosin Beta-4 supplies an actin-sequestration signal driving cell migration [2][3]. The two are described as complementary but largely non-overlapping — an extrapolation, not a finding from a controlled combination study [6].
Is there any study showing BPC-157 and TB-500 work better together (synergy)?
No. No peer-reviewed combination study defines a synergy ratio, dose, or endpoint for the two given together; the 2025 systematic review of BPC-157 in orthopaedic sports medicine makes no mention of TB-500 or combination use [6]. The synergy is a theoretical extrapolation from each peptide's separate mechanism.
Is the 'Wolverine' synergy claim actually proven?
No. The synergy claim is a theoretical extrapolation from two independently characterized, largely non-overlapping mechanisms [2][3]. No controlled head-to-head or combination study has defined a synergistic dose, ratio, or endpoint, and 2025-2026 reviews treat both compounds as investigational with scarce human safety data [6][7].
How does TB-500 work (actin / Thymosin Beta-4)?
TB-500's LKKTETQ motif binds monomeric G-actin 1:1 and sequesters it. X-ray crystallography of a gelsolin-domain-Thymosin-Beta-4 hybrid bound to actin established this dual-end capping mechanism — the structural basis for regulating the actin dynamics that drive cell migration [3].
How does BPC-157 work compared to TB-500?
BPC-157 is pro-angiogenic and cytoprotective: it up-regulates VEGFR2 and activates the VEGFR2-Akt-eNOS pathway [2]. TB-500 acts on the cytoskeleton by sequestering G-actin to regulate cell migration [3]. The two operate through largely separate pathways — the premise of the combination rationale.
Do BPC-157 and TB-500 promote angiogenesis (new blood vessels)?
Both are reported to, by distinct routes. BPC-157 up-regulates VEGFR2 and accelerates blood-flow recovery in ischemic muscle [2]; Thymosin Beta-4 (TB-500's parent) promotes endothelial migration and angiogenesis in wound and aged-animal models [4]. These are parallel, not shared, angiogenic mechanisms.
Evidence and efficacy
These answers cover the tissue-specific findings and the human-data record, with the consistent flag that the evidence is single-compound and largely rodent.
Are there human clinical trials on the BPC-157 + TB-500 combination?
There are no controlled clinical trials of the combination for any indication. Human data exist only for the individual constituents and are thin: BPC-157 has three small pilot studies, and the human "TB-500" data are actually for full-length Thymosin Beta-4, not the heptapeptide [4][5][8].
Does the BPC-157 TB-500 blend help tendon and ligament injuries?
Evidence is preclinical and single-compound. BPC-157 accelerated healing of a fully transected rat Achilles tendon across biomechanical, functional, and microscopic measures [1]; TB-500's parent protein enhanced rat ligament healing [4]. No combination study tests the blend in tendon or ligament injury [6].
What is the latest research on BPC-157 and TB-500?
The most defensible recent literature is review-level: a 2025 systematic review of BPC-157 in orthopaedic sports medicine (level IV-V evidence, no clinical safety data) [6], a 2025 narrative review treating BPC-157 as investigational [8], and a 2026 Sports Medicine review of unapproved musculoskeletal peptides noting animal-model promise but scarce human safety data [7].
What do doctors and reviews say about the BPC-157 + TB-500 blend?
Recent academic reviews consistently describe the constituents as investigational: BPC-157 shows preclinical promise but rests on level IV-V evidence with no clinical safety data [6], and reviews of unapproved peptide therapies warn of scarce human safety data, potential for serious harm, and operation outside regulatory oversight [7][8].
Dose, route, and handling
These answers cover the practical dosing and reconstitution questions, with the same flag throughout: no validated dose for the blend.
How do you cycle BPC-157 and TB-500?
There is no validated cycle for the blend. Community "loading then maintenance" protocols and fixed-ratio vials (e.g. 10 mg + 10 mg) have no basis in controlled human trials; the underlying studies are animal models dosed per body weight, and one stroke study found dosing non-monotonic — higher was not better [4].
What is the half-life of BPC-157 and TB-500?
No validated human PK half-life exists for either constituent at research-use doses, and none for the blend. BPC-157's elimination half-life was reported under 30 minutes in a rat/dog study; human full-length Thymosin Beta-4 showed dose-proportional PK, but no specific half-life is established for the TB-500 heptapeptide [4].
How do you reconstitute a BPC-157 / TB-500 blend (10mg)?
Both constituents are supplied as lyophilized powders for research use, reconstituted in bacteriostatic or sterile water and refrigerated. In unregulated "Wolverine" material the actual BPC-157:TB-500 ratio, identity, and purity are not guaranteed, so no validated reconstitution figure can be stated for the blend [1][5].
Safety and the tumor signal
These answers cover the safety questions honestly: no controlled human safety data for the blend, and a real theoretical concern around Thymosin Beta-4.
What are the side effects of BPC-157 and TB-500?
Human safety data are limited. Full-length Thymosin Beta-4 was well tolerated in Phase 1 intravenous studies, but the blend's combination safety is unproven [4]; 2026 review evidence warns of scarce human safety data and potential for serious harm with unapproved musculoskeletal peptides used outside regulatory oversight [7].
Does TB-500 promote tumor growth?
Thymosin Beta-4 has been implicated in tumor metastasis and angiogenesis: the same pro-migratory, pro-angiogenic properties that aid repair could theoretically support tumor progression [4]. This is a theoretical safety consideration, not a demonstrated effect of the blend in humans; long-term human data are absent.
Regulatory and access
These answers summarize the regulatory record; the Wolverine legal status and FDA 503A category page covers it in full and cites FDA.
Are BPC-157 and TB-500 FDA approved or banned by WADA?
Neither is FDA-approved for human use, and both are prohibited by WADA (BPC-157 under the S0 non-approved-substances category; TB-500 / Thymosin Beta-4 under prohibited peptide/growth-factor and tissue-repair categories). In 2023 FDA placed both constituents in 503A Category 2 [9]. The blend has no approved therapeutic indication.
Is Wolverine legal?
Neither constituent is an FDA-approved drug and the blend has no approved therapeutic indication; both are sold by research suppliers for laboratory use only [9]. Both are currently 503A Category 2 and are not within FDA's enforcement-discretion policy for compounding, and both are WADA-prohibited.
Can you get BPC-157 from a compounding pharmacy?
Currently, access is restricted. FDA placed BPC-157 in 503A Category 2 — bulk substances not within its enforcement-discretion policy — effective with the September 29, 2023 list update, so it is not eligible for routine 503A compounding while that status stands [9]. BPC-157 is on the July 23-24, 2026 PCAC agenda as a 503A bulks-list candidate — a scheduled evaluation, not a change in current status [10].
What is the FDA 503A status of Wolverine?
Both components are FDA 503A Category 2 bulk substances today, effective with the September 29, 2023 update, and neither is FDA-approved, so the blend has no current 503A compounding pathway [9]. Both are on the July 23-24, 2026 PCAC agenda as 503A bulks-list candidates — a scheduled review, not a decision [10].